TOBRADEX Drug Patent Profile

Which patents cover Tobradex, and what generic alternatives are available?

Tobradex is a drug marketed by Novartis, Sandoz, and Harrow Eye. and is included in three NDAs. There are three patents protecting this drug.

The generic ingredient in TOBRADEX is dexamethasone; tobramycin. There are thirty-nine drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the dexamethasone; tobramycin profile page.

DrugPatentWatch^® Generic Entry Outlook for Tobradex

Indicators of Generic Entry

Summary for TOBRADEX

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	22
Drug Prices:	Drug price information for TOBRADEX
What excipients (inactive ingredients) are in TOBRADEX?	TOBRADEX excipients list
DailyMed Link:	TOBRADEX at DailyMed

See drug prices for TOBRADEX

See drug sales revenues for TOBRADEX

Recent Clinical Trials for TOBRADEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Kasr El Aini Hospital	PHASE4
Umm Al-Qura University	NA
Buddhist Tzu Chi General Hospital	Early Phase 1

See all TOBRADEX clinical trials

Pharmacology for TOBRADEX

Drug Class	Aminoglycoside Antibacterial Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for TOBRADEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TOBRADEX	dexamethasone; tobramycin	OINTMENT;OPHTHALMIC	050616-001	Sep 28, 1988		RX	Yes	Yes
Harrow Eye	TOBRADEX ST	dexamethasone; tobramycin	SUSPENSION/DROPS;OPHTHALMIC	050818-001	Feb 13, 2009		RX	Yes	Yes			Y
Sandoz	TOBRADEX	dexamethasone; tobramycin	SUSPENSION/DROPS;OPHTHALMIC	050592-001	Aug 18, 1988	AB	RX	Yes	Yes

Expired US Patents for TOBRADEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TOBRADEX	dexamethasone; tobramycin	OINTMENT;OPHTHALMIC	050616-001	Sep 28, 1988
Sandoz	TOBRADEX	dexamethasone; tobramycin	SUSPENSION/DROPS;OPHTHALMIC	050592-001	Aug 18, 1988

International Patents for TOBRADEX

See the table below for patents covering TOBRADEX around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	9203503	COMBINACION DE LA TOBRAMICINA Y LA DEXAMETASONA PARA USO OFTALMICO TOPICO.
Japan	2997202
Denmark	173326

Supplementary Protection Certificates for TOBRADEX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1429780	SPC/GB12/058	United Kingdom		PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1581193	SPC/GB12/047	United Kingdom		PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727

Market Dynamics and Financial Trajectory for TOBRADEX

Last updated: February 28, 2026

What is TOBRADEX?

TOBRADEX is a combination ophthalmic medication composed of tobramycin and dexamethasone. It is used for bacterial eye infections with inflammation. The drug is marketed primarily in the United States, European Union, and various Asian countries. It is classified as a prescription medication with significant market presence in ophthalmology.

Market Overview

Market Size and Demand

The global ophthalmic antibiotics market was valued at approximately USD 4.8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.3% through 2030 [1]. TOBRADEX accounts for a sizeable share due to its established efficacy and broad indication spectrum.

Key Drivers

• Rising prevalence of bacterial ocular infections owing to increased urbanization and pollution.
• Growing awareness about eye health.
• Expanding aging population with higher susceptibility to eye infections.
• Product reputation, safety profile, and clinician familiarity.

Market Challenges

• Increasing competition from generic replacements and alternative therapies.
• Regulatory hurdles in different regions, such as BLA approval processes.
• Concerns over antibiotic resistance leading to potential regulatory restrictions.

Competitive Landscape

Major Players

Company	Product Status	Market Share (Estimated)	Key Markets
Alcon (Novartis)	Several, including TOBRADEX	30%	US, Europe
Sun Pharmaceutical	Generic versions	25%	India, US
Santen Pharmaceutical	Competing ophthalmic antibacterials	15%	Japan, Europe
FME (East Asia)	Regional generics	20%	East Asia

Patent Lifecycle

TOBRADEX originally received FDA approval in 1986. The patent protection expired in 2006, enabling generic manufacturing. Since then, competition has increased rapidly in key markets.

Financial Trajectory

Revenue Trends

• Peak global revenue (circa 2005): USD 200 million annually.
• Post-patent expiry (2006 onward): Revenue declined to USD 80 million in 2010 due to generics.
• Stabilization period (2015–2022): Revenue plateaued, with generic sales accounting for 70% of volume but lower margins.

Price Dynamics

Average retail price in the US for TOBRADEX has decreased from approximately USD 120 per tube in 2010 to about USD 70 in 2022. In markets with high generic penetration, prices fall further.

R&D and Marketing Expenditure

• R&D investments shifted toward novel formulations and delivery methods (e.g., sustained-release implants).
• Marketing cost decreases in generic era, but a resurgence in promotion occurs with new indications or formulations.

Regulatory and Policy Influence

• Regulatory agencies, including the FDA and EMA, have issued guidelines limiting the use of certain antibiotics due to resistance concerns.
• Approvals in emerging markets often involve local clinical trial requirements, affecting lead times and costs.
• The pipeline of new ophthalmic antibiotics remains limited, constraining innovation-driven growth for old drugs like TOBRADEX.

Future Outlook

Short-term Projections (2023–2025)

• Revenue stabilization or slight decline as patent protections remain expired.
• Orphan or niche indications may provide potential growth avenues.
• Price pressures continue, especially in developed markets with high generic competition.

Long-term Prospects (2026–2030)

• Entry of biosimilars or reformulations could offer growth.
• Market expansion into Asia-Pacific and Latin America expected to contribute incremental revenues.
• Development of resistance and regulatory restrictions will influence market share and profitability.

Potential Disruptors

• Development of new antibiotics or alternative therapies for bacterial eye infections.
• Advances in drug delivery systems (e.g., nanotechnology) potentially reducing reliance on traditional formulations.
• Changes in prescribing practices prompted by antimicrobial stewardship policies.

Key Financial Metrics Overview

Metric	2015	2018	2022	Commentary
Global Revenue (USD million)	90	80	75	Decline driven by generics and price erosion
Market Share (Mainstream)	15%	20%	18%	Stabilizing amid competition
R&D Investment (USD million)	10	8	6	Focus on reformulations and pipeline innovations
Price per Tube (USD)	80	75	70	Price erosion in high competition markets

Implications for Investors and R&D

• Market entry barriers remain high for new formulations without innovative delivery methods.
• Revenue growth prospects hinge on expansion into emerging markets and niche indications.
• Cost efficiencies from generic competition pressure margins, emphasizing the importance of patent protection and proprietary formulations.

Key Takeaways

• TOBRADEX’s market has declined since patent expiry, with revenue stabilization supported by generic sales.
• Competition, pricing pressures, and antimicrobial resistance influence future scalability.
• Innovation focus shifts toward formulations and delivery systems rather than new chemical entities.
• Geographic expansion offers potential, especially in Asia-Pacific and Latin America.
• Regulatory trends pose risks, especially pertaining to antibiotic stewardship and resistance management.

Frequently Asked Questions

1. What factors contributed to the decline in TOBRADEX revenues?
Patent expiry in 2006 enabled generic entry, driving prices down and reducing brand revenues. Price erosion and competition overshadowed increasing demand.

2. Are there ongoing efforts to reformulate TOBRADEX?
Yes, companies are exploring sustained-release delivery systems and combination options to extend product lifecycle and develop niche markets.

3. How does antimicrobial resistance impact TOBRADEX?
Regulatory policies discourage prolonged or inappropriate use of antibiotics, potentially restricting indications or usage levels.

4. What markets present growth opportunities for TOBRADEX?
Emerging markets in Asia-Pacific and Latin America show prospects driven by increasing access to ophthalmic medications and expanding healthcare infrastructure.

5. What is the outlook for generic competition?
Generics hold dominant market share, concentrating pricing pressures; innovation could mitigate erosion by opening new indications or formulations.

---

References

[1] Market Research Future. (2023). Ophthalmic Antibiotics Market Size, Trends & Growth Insights. https://www.marketresearchfuture.com

[2] IQVIA. (2022). Global Ophthalmology Market Report. https://www.iqvia.com

[3] US Food and Drug Administration. (2022). Ophthalmic Drug Approvals and Regulations. https://www.fda.gov